These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35727409)

  • 1. Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes.
    Zhou K; Isaacs D
    Curr Cardiol Rep; 2022 Sep; 24(9):1159-1167. PubMed ID: 35727409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes.
    Dadlani V; Pinsker JE; Dassau E; Kudva YC
    Curr Diab Rep; 2018 Aug; 18(10):88. PubMed ID: 30159816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Artificial Pancreas and Type 1 Diabetes.
    Nwokolo M; Hovorka R
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1614-1623. PubMed ID: 36734145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do-It-Yourself (DIY) Artificial Pancreas Systems for Type 1 Diabetes: Perspectives of Two Adult Users, Parent of a User and Healthcare Professionals.
    Ahmed SH; Ewins DL; Bridges J; Timmis A; Payne N; Mooney C; MacGregor C
    Adv Ther; 2020 Sep; 37(9):3929-3941. PubMed ID: 32696329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
    Beck RW; Kanapka LG; Breton MD; Brown SA; Wadwa RP; Buckingham BA; Kollman C; Kovatchev B
    Diabetes Technol Ther; 2023 May; 25(5):329-342. PubMed ID: 37067353
    [No Abstract]   [Full Text] [Related]  

  • 6. Is an artificial pancreas (closed-loop system) for Type 1 diabetes effective?
    Boughton CK; Hovorka R
    Diabet Med; 2019 Mar; 36(3):279-286. PubMed ID: 30183096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system.
    Hanazaki K; Munekage M; Kitagawa H; Yatabe T; Munekage E; Shiga M; Maeda H; Namikawa T
    J Artif Organs; 2016 Sep; 19(3):209-18. PubMed ID: 27142278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 Diabetes.
    Schoelwer MJ; Robic JL; Gautier T; Fabris C; Carr K; Clancy-Oliveri M; Brown SA; Anderson SM; DeBoer MD; Cherñavvsky DR; Breton MD
    Diabetes Technol Ther; 2020 Aug; 22(8):594-601. PubMed ID: 32119790
    [No Abstract]   [Full Text] [Related]  

  • 10. A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G.
    Jeyaventhan R; Gallen G; Choudhary P; Hussain S
    Diabetes Obes Metab; 2021 Aug; 23(8):1989-1994. PubMed ID: 33999488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.
    Wilinska ME; Budiman ES; Taub MB; Elleri D; Allen JM; Acerini CL; Dunger DB; Hovorka R
    J Diabetes Sci Technol; 2009 Sep; 3(5):1109-20. PubMed ID: 20144424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical review of the t:slim X2 insulin pump.
    Berget C; Lange S; Messer L; Forlenza GP
    Expert Opin Drug Deliv; 2020 Dec; 17(12):1675-1687. PubMed ID: 32842794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability.
    Anderson SM; Dassau E; Raghinaru D; Lum J; Brown SA; Pinsker JE; Church MM; Levy C; Lam D; Kudva YC; Buckingham B; Forlenza GP; Wadwa RP; Laffel L; Doyle FJ; DeVries JH; Renard E; Cobelli C; Boscari F; Del Favero S; Kovatchev BP
    Diabetes Technol Ther; 2019 Feb; 21(2):73-80. PubMed ID: 30649925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commercial hybrid closed-loop systems available for a patient with type 1 diabetes in 2022.
    Seget S; Tekielak A; Rusak E; Jarosz-Chobot P
    Pediatr Endocrinol Diabetes Metab; 2023; 29(1):30-36. PubMed ID: 37218723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.
    Weinzimer SA; Steil GM; Swan KL; Dziura J; Kurtz N; Tamborlane WV
    Diabetes Care; 2008 May; 31(5):934-9. PubMed ID: 18252903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who needs an artificial pancreas? (？).
    Winikoff J; Drexler A
    J Diabetes; 2013 Sep; 5(3):254-7. PubMed ID: 23601378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
    Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
    Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.